GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » Debt-to-EBITDA

SMO Clinplus Co (SZSE:301257) Debt-to-EBITDA : 0.09 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SMO Clinplus Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥5.9 Mil. SMO Clinplus Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥3.2 Mil. SMO Clinplus Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥105.3 Mil. SMO Clinplus Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.09.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SMO Clinplus Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:301257' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03   Med: 0.06   Max: 0.1
Current: 0.06

During the past 7 years, the highest Debt-to-EBITDA Ratio of SMO Clinplus Co was 0.10. The lowest was 0.03. And the median was 0.06.

SZSE:301257's Debt-to-EBITDA is ranked better than
96.08% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.775 vs SZSE:301257: 0.06

SMO Clinplus Co Debt-to-EBITDA Historical Data

The historical data trend for SMO Clinplus Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co Debt-to-EBITDA Chart

SMO Clinplus Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial - 0.10 0.06 0.05 0.06

SMO Clinplus Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.05 0.07 0.09

Competitive Comparison of SMO Clinplus Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, SMO Clinplus Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMO Clinplus Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's Debt-to-EBITDA falls into.



SMO Clinplus Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SMO Clinplus Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.606 + 5.476) / 172.19
=0.06

SMO Clinplus Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.856 + 3.229) / 105.284
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


SMO Clinplus Co  (SZSE:301257) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


SMO Clinplus Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SMO Clinplus Co (SZSE:301257) Business Description

Traded in Other Exchanges
N/A
Address
No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
Executives
Lai Chun Bao Director
Ma Lin Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines